NAT 2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic–Pharmacokinetic Cohort Study
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf511 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Napon Hiranburana und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Antitubercular Agents, HIV Infections, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Health Systems Research Institute, Ratchadapiseksompotch Fund, Faculty of Medicine.
Abstract (Originalsprache)
Background
The N-Acetyltransferase (NAT2) slow acetylator phenotype has been associated with a higher risk of isoniazid (INH)-induced hepatotoxicity. We investigated the association between NAT2 genotypes with inferred acetylator status, hepatotoxicity, and INH pharmacokinetics in Thai people living with HIV (PLWH) receiving INH-based Tuberculosis (TB) preventive or treatment regimens.
Methods
In this prospective cohort study of Thai PLWH initiating INH-based regimens; NAT2 genotyping classified participants as slow (SA), intermediate (IA), or rapid acetylators (RA). Hepatotoxicity was defined as transaminase elevations more than 2.5 times the upper limit of normal (ULN). Multivariable logistic regression identified genotypes and factors associated with hepatotoxicity. A pharmacokinetic (PK) substudy assessed INH exposure across phenotypes.
Results
Of 894 participants, 32.4% were SA, 41.2% IA, and 26.4% RA. Hepatotoxicity occurred in 10.9% overall and was highest in SA (15.2%). SA had increased hepatotoxicity risk versus RA (adjusted odds ratio [aOR] 2.43; 95% CI: 1.32–4.48). Genotypes NAT2*6A/*6A (aOR 1.84) and NAT2*7B/*7B (aOR 4.46) were associated with increased risk; NAT2*4/*4 was protective (aOR 0.33). Other independent risk factors included high baseline alanine aminotransferase (ALT), HCV co-infection, 2HRZE/4HR regimen (vs 1HP), and efavirenz-based antiviral therapy (vs dolutegravir). In the PK substudy (n = 93), INH exposure assessed by the area under the concentration time curve from 0 to 24 h, was significantly increased by approximately 2-fold in SA, regardless of anti-TB regimen.
Conclusions
NAT2 SA phenotype, particularly *6A/*6A and *7B/*7B genotypes, is associated with an increased risk of anti-tuberculosis-induced hepatotoxicity and higher INH exposure in Thai PLWH. Incorporating NAT2-guided dosing may enhance safety of INH-containing regimens in PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand.
- Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- The Kirby Institute, University of New South Wales, Sydney, Australia.
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
ORCID-Profile: Napon Hiranburana, Stephen J Kerr, Pattama Torvorapanit, Weeraya Phaisal, Pajaree Chariyavilaskul, Yong-Soon Cho, Jae-Gook Shin, Anchalee Avihingsanon
Förderung
- Health Systems Research Institute
- Ratchadapiseksompotch Fund
- Faculty of Medicine
- Chulalongkorn University
- Mahidol University
Zitieren
APA
Hiranburana, N., Sophonphan, J., Kerr, S. J., Ubolyam, S., Usawakidwiree, W., Torvorapanit, P., Suwanpimolkul, G., Phaisal, W., Chariyavilaskul, P., Cho, Y. S., Shin, J. G., Mahasirimongkol, S., & Avihingsanon, A. (2026). NAT 2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic–Pharmacokinetic Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf511
Vancouver
Hiranburana N, Sophonphan J, Kerr SJ, Ubolyam S, Usawakidwiree W, Torvorapanit P, et al. NAT 2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic–Pharmacokinetic Cohort Study. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf511
BibTeX
@article{Hiranburana2026,
author = {Hiranburana, Napon and Sophonphan, Jiratchaya and Kerr, Stephen J and Ubolyam, Sasiwimol and Usawakidwiree, Warat and Torvorapanit, Pattama and Suwanpimolkul, Gompol and Phaisal, Weeraya and Chariyavilaskul, Pajaree and Cho, Yong-Soon and Shin, Jae-Gook and Mahasirimongkol, Surakameth and Avihingsanon, Anchalee},
title = {NAT 2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic–Pharmacokinetic Cohort Study},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf511}
}
EUVIMED